Dapadax Vgm 10/100/1000mg Tablet

DAPADAX VGM 10/100/1000 mg Tablet is a triple fixed-dose oral antidiabetic combination consisting of:

• Dapagliflozin (10 mg): An SGLT2 inhibitor that lowers blood glucose by promoting glucose excretion in urine

• Metformin (1000 mg): A biguanide that reduces hepatic glucose production and improves insulin sensitivity

• Vildagliptin (100 mg): A DPP-4 inhibitor that enhances insulin secretion and reduces glucagon levels in a glucose-dependent manner

This combination is intended for adults with Type 2 Diabetes Mellitus (T2DM) who require multi-drug therapy for adequate glycemic control.

USES

• Treatment of Type 2 Diabetes Mellitus in adults

• Used when diet, exercise, and dual oral therapy do not sufficiently control blood glucose levels

• May be part of a broader treatment plan including lifestyle changes and/or additional medications

BENEFITS

• Triple action mechanism targeting different aspects of glucose metabolism:

  • Dapagliflozin: Eliminates excess glucose via urine

  • Metformin: Suppresses liver glucose production and enhances insulin sensitivity

  • Vildagliptin: Increases insulin release and lowers glucagon after meals

• Weight loss or weight neutral effect

• Low hypoglycemia risk (when not used with insulin or sulfonylureas)

• Potential cardiovascular and renal benefits (mainly due to dapagliflozin)

• Once/twice-daily fixed-dose combination improves adherence and convenience

SIDE EFFECTS

Common Side Effects:

• Increased urination

• Genital infections (e.g., fungal)

• Urinary tract infections

• Nausea, vomiting, diarrhea (mainly due to Metformin)

• Headache

• Cold-like symptoms (nasopharyngitis)

Less Common / Serious Side Effects:

• Lactic acidosis (rare but serious; linked to Metformin in renal/hepatic impairment)

• Diabetic ketoacidosis (rare; associated with dapagliflozin)

• Pancreatitis (rare; associated with DPP-4 inhibitors)

• Hypoglycemia (more likely when used with insulin/sulfonylureas)

• Allergic skin reactions or rash